Mission Therapeutics nominated as Biotech and Money 2017 Awards Double Finalist
Cambridge, UK – 9 June 2017 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, has been announced as a finalist in two categories for the Biotech and Money 2017 Awards.
The Biotech and Money 2017 Awards celebrate funding, finance and investment successes over the past 12 months across the British Life Sciences sector.
Mission has been nominated for UK Growth Life Sciences Company of the Year and UK Life Science Private CEO of the Year.
The first nomination is for Mission’s novel approach to treating a range of clinical indications by targeting human DUBs and overcoming specificity and selectivity barriers, progressing the development of promising therapies. The second nomination is for CEO Anker Lundemose, who has played a pivotal role in in Mission’s transition from discovery to clinical development, leveraging over two and a half decades of biopharma expertise.
At last year’s Awards, Mission won the ‘One to Watch’ Private UK Life Science Company of the Year Award.
Winners of each category are determined on the basis of online voting (which can be done here http://bit.ly/2r8Zne2) and a live voting session during the Awards dinner, which will be held on 14 September in London.
Details of the event are here: Biotech and Money Assembly and Awards Gala Dinner
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.
In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.
About Biotech and Money Awards 2017
Biotech and Money Assembly and Awards is a 250 person Gala Dinner celebrating the UK’s funding, finance and investment successes in the sector over the last 12 months. Leading lights and emerging stars, C-suite executives, impactful investors and powerful KOLs in the sector will be celebrating at one of London’s finest banqueting halls; Merchant Taylors Hall on 14th September 2017, from 6pm-11pm.
For more information, please visit the website: http://www.biotechandmoney.com/gala-dinner
For more information, please contact:
Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0) 1223 497199
Instinctif Partners
Melanie Toyne-Sewell / Eileen Paul / Priya Kalia
Tel: +44 (0) 20 7457 2020
missiontherapeutics@instinctif.com
Westwicke Partners (U.S.)
Chris Brinzey
Tel: +1 339-970-2843
